Amit Malhotra: The Expanding Role of Upadacitinib Across Autoimmune and Inflammatory Disorders
Amit Malhotra, Chairman of Headquarters Committee at IADVL, shared a post on LinkedIn:
“Had the privilege of attending a highly informative CME on Upadacitinib at Dehradun.
The scientific discussions highlighted how JAK-STAT inhibitors are transforming the management of several chronic inflammatory and autoimmune disorders.
Upadacitinib works by selectively inhibiting Janus Kinase (JAK) pathways, thereby blocking inflammatory signals transmitted through the JAK-STAT pathway.
This targeted mechanism helps reduce inflammation, itching, pain, and tissue damage while improving patient outcomes.
The molecule has demonstrated impressive efficacy in conditions such as Atopic Dermatitis, Alopecia Areata, Vitiligo, Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Ulcerative Colitis.
With rapid onset of action and sustained disease control, JAK inhibitors represent a significant advancement in precision medicine.
Grateful to the organizers and faculty for an enriching academic experience and valuable clinical insights.
Caution: Do not self medicate.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care